Allergy Drug May be Effective in Kidney Disease
News Oct 22, 2015
Dr Poh-Yi Gan and Kim O’Sullivan from the Centre for Inflammatory Diseases have shown in animal models that allergy drug disodium cromoglycate can be used as an effective treatment for vasculitis.
Vasculitis, or inflammation of the blood vessels, is an autoimmune disease that can lead to serious organ damage, especially in the kidneys.
“For the first time, our research has uncovered a new role for mast cells and their effect in non-allergic inflammatory kidney disease,” said lead study author Dr Gan.
“Mast cells are immune cells that are traditionally thought to be responsible for allergic diseases such as asthma, hay fever, and food allergy including anaphylaxis.”
While mast cells are important in suppressing autoimmunity, they can also make autoimmune diseases such as vasculitis worse.
“Using disodium cromoglycate in a mouse model of vasculitis stabilises the harmful effects of mast cells and leaves their immune modifying effect intact,” said lead co-author Ms O’Sullivan.
“I also studied kidney biopsies from patients with vasculitis and found that activated mast cells were prominent, suggesting they play an injurious role in the human disease.”
Disodium cromoglycate, commonly used in Europe for allergic conditions including asthma, is relatively cheap and has very few side effects.
“This research shows we may be able to repurpose an existing drug for different forms of inflammation,” said Head of the Centre for Inflammatory Diseases, Professor Richard Kitching.
“Current treatments for vasculitis suppress the immune system and have many nasty side-effects, however, disodium cromoglycate is a non-toxic medication that may dampen acute flares of vasculitis.”
Importantly, this breakthrough research may lead to a treatment for vasculitis that effectively manages inflammation and symptoms while not suppressing the immune system.
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE